Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well this sucks, wasn't wound pros paying the so called license deals?
Interesting your findings on Dr. Chris Otiko is no longer employed with Wound Pros. ViaDerma took lots of pride with the association. Anyways, I am not surprised either, non-profit organizations don’t take well on the long road people with such questionable reputation as the Dr describes in his own BIO, even if he got exonerated from such federal situation. I am really concerned and if some of you are willing to team up to open an investigation case, count with me as well. I am ready to lawyer myself up and begin to knock the SEC’s doorbell over this possible Ponzi set up.
Sad because he got something good going in here but that is what the greed built in Men drive you to do….
If he is natty, he will soon learn that it is not what you don’t know that get you in trouble but that you think it is but really isn’t!!
I wouldn't call them smoke signals. Shareholders are genuinely concerned about their investments in this company and they really should be.
Now Otiko dilutes another 40 million shares. No reason given by him or the useless PR guy either. We're far past the point of being patient enough to see results or have any inclination to what they are actually doing with the business. Still no mentions about Nupelo, Dubai deal, or all of those overseas shipments in March that they PR'd and tweeted about. No inventory on their books either while Otiko gives himself $700,000 but now claims the company is in its best place financially? No one believes this BS. Where are all the sales for the strongest topical antibiotic in the world?
At this point, it will likely take a class action lawsuit or filing multiple SEC complaints to uncover what they are actually doing with an investigation and discovery.
email cotiko@thewoundpros.com and get this response.
Thank you for your email. Dr. Chris Otiko is no longer employed with Wound Pros. Your email will be directed to the appropriate Wound Pros department for prompt handling. If you need immediate assistance, please contact Dr. Bill Releford at DrBill@thewoundpros.com or Attorney Keith Greer at KGreer@thewoundpros.com.
What is going on here? Isn't he the cofounder? He most likely got fired or maybe, just maybe he's going to fully focus on growing Viaderma now. Doubtful that is the case but a very small chance this might be it.
Dr will increase the A/S next. If he can’t dilute and get free product, this company is worthless to him
"When $99 . . . 50% price increase, is baffling" . . . Stupid things happen when dumb people have an idea . . . someone here in management must have had a thought
When $99 price point is ONLY generating from <$100 to <$700 in gross profit per quarter, per the clause below, over last six quarters, since restart of online sales, and after all of Intent Sciences promotion, even consideration of price increase, much less 50% price increase, is baffling.
On January 1, 2017, the Company entered into a licensing and distribution agreement with Biogenx, Inc. for the purpose of commercializing and distributing a topical antibiotic product to be branded VitaStem. On August 1, 2018, Biogenx, Inc. changed its legal entity name as Viaderma Distribution, Inc. The product will carry the Company’s tetracycline-based technology. This product will be separately registered with the FDA. Pursuant to the agreement, the Company will receive 50% of gross profit from sales of Vitastem. For purposes of the agreement, gross profit is defined as total revenues less cost of production, distribution and marketing. In addition ViaDerma will receive an additional 5% of gross sales as a licensing fee. The agreement was terminate on Marche 31, 2024 unless extended by both parties. Viaderma Distribution, Inc. (Formerly Biogenx, Inc.) has the right to terminate the agreement early with two month notice if it deems the arrangement to not be financially viable. This agreement was renewed on January 1, 2023.
So he can make an extra $50 per bottle, why else
And why all of a sudden did he increase the price per bottle to $149??? He didn’t even mention anything on that front in the last PR!
Only reason In my own opinion that Dr Otiko finally did a PR the other day was because of the “Smoke Signals” he probably was seeing of sick and tired investors who were speaking about going to file a complaint against him and the company for that whole Bullshit loan and definition of it in the quarterly.
Even the PR stinks to the high heavens as Bullshit. He probably came up with this “hiring” employees so that he can burn up the $1 million in cash the company is supposed to have on hand!!!!
I won’t believe anything further until I see concrete proof.
Disappointing, whereas this will likely turn trickle of product sales revenue into a drip.
Ohh my gosh, what is all this $HIT over me? Did the $hit hit the Fan? Yes it did because it spread all over the room. You are all ViaDerma dirty. Hahahahahahaha
Relax folks, ViaDerma been here before, better get these cheapies before it moves
I sure hope the doc treats his patients better than he treats his investors
$52 in trading volume today. No interest in this POS disaster.
I am still chasing answer to licensing revenue growing discrepancy. Sent follow-up email this morning whereas promised answer has not been received (2+ weeks and counting). I will pass along answer, if and when it is received.
They talked about being in 50 states over a year ago and to date, they're not even in half the US. Based on the filings, they have no new sales but more of the same BS PRs and no one at Viaderma will even answer shareholders for the most part.
It is finally at 0.005 level. We been around here before. History repeats itself in here for sure. Buy the dip while you can, this ponzi moves per season
All forms of vitastem with tetracycline is the old formula that stains everything. Maybe the old formula being pushed in his native African nations?
Just went to order a bottle vitastem from there website. They have raised price of 55ml bottle to $149. That's 50% increase in price from a month ago.
One or two international sales would be big time. Domestic expansion to our previously talked about 50 states woul almost yield the same upward results. Just looks so good in the planning paperwork but fails to catch on. Either one would provide more revenue. I think it is coming..
Don't think so. It's just licensing fees and based on their financials and the only deal they seem to have on their books.
It would be great if the pr guy rich or otiko would actually answer shareholders questions and concerns so everyone could have a better understanding of what they are actually doing and sales in the pipeline.
International sales have been talked about for years now and nothing ever comes to fruition, just like them shipping tons of product out in March. Now we just get more crickets and BS PRs.
Does VDRM book revenues from TetraCyte sales that go through Wound Pros Company?
I email dr Otiko and re never a very quick response that the good doctors no longer is employed there?????? What to heck is going on, who running thus place?
Doesn't vdrm have a patent for the vitastem?
Old news. This was done years ago.
Try emailing Otiko at the wound pros.
cotiko@thewoundpros.com for answers about it and see what he has to say.
CEO is rarely inclined to properly or promptly inform shareholders, to put it mildly. However, best guess is that it will fall under similar (but currently unannounced) clause like this, from 1Q24 financial report, for countries versus states: "On January 4, 2021, the Company entered into a three-year exclusive distributor and licensing agreement with an affiliate of the Company. The Company provides the FDA registered medication, Tetracyte, to the affiliate’s medical practices in six States. The affiliates created their own private label for the wound care utilizing the Company’s technology." and will be at some as yet, unpublished licensing rate.
excelsiorvision I don't care about the last 7 yrs.
I does appear to be launching under The Wounds Pro branding. :)
Don't hold your breathe. Everyones been waiting for years for one but only get continual BS from them.
I agree 💯. We should be trading much higher than this for sure. Still when I am dreaming I see in the clouds 7-10 by January.
"We are currently in the strongest financial position in which we have ever been, said, Dr. Christopher Otiko, President of ViaDerma. This is the right time for us to bring on additional staff that will be in responsible for expanding our international sales." Don't let the sky is falling gang scare you out. :)
I posted this a long while back.............and was attacked. 😂 😂 😂 😂
It looks like another one Otikos back door companies besides wound pros is called national institutes of health (NIH)
Ya … the “doc’s” new product is “tetracyte” not Vitastem. Wonder who is producing it and who is receiving all the proceeds from the sale of the “new” INNOVATIVE product. It sounds like the EXACT same description of Vitastem Ultra but labeled tetracyte for wound pro’s exclusively. WTF is this sh!t. Are we the share holders getting back door swindled ??? Why does the same product need to be labeled differently ??? Hey doc … Why doesn’t wound pros use and sell Vitastem Ultra so both of YOUR companies benefit (especially VDRM) for you AND the shareholders sake ???
Even a blind hog finds an acorn now & then
You can ask the editor:
Editor In Chief IKENNA EMEWU For adverts, please call +234-812-099-7006 This site is owned and operated by the AFRI-CHINA MEDIA CENTRE LIMITED
Why no mention of VDRM or Viaderma in the first article? Almost as if the Doc's privately held company is competing against VDRM.
Thanks for pointing that out. I only checked the quarterly report, Unfortunately, it is of the same time period (2017/2018). With ONLY <$0.7K of product sales for each of last 6 quarters, something needs to break the product sales revenue into 4 digits (5 digits, 6 digits, etc.). Maybe, it will be that after all this time, if the asserted information is ultimately documented in financial report as spot on.
The point would be, with no anywhere recent, up to date information in the 1Q24 financial report, or any other "official" source, how would anyone know, legitimately, about sales in Canada, even if true?
Old news. Please get to a point. What point are you trying to make? Chuckles!!!
Tell us something we don’t know
For what it is worth, since Section 4) Issuer's Business, Products and Services is 3-7 years out of date, the only mention of Canada (via word search), in 1Q24 financial report, is:
On January 1, 2018, the Company entered into a licensing agreement with SSP Asset Management Corp., an organization incorporated under the laws of Alberta, Canada (“SSP”). The license granted SSP the right to use the Company’s transdermal technology for use within certain products. The Company will receive Fifty Percent (50%) of the net profits of any products sold by SSP. The term of the license is 25 years and is exclusive for a minimum of two years on any new products developed by SSP. The Company also issued 20 million restricted common shares to the shareholders of SSP to assist in the development of the new products.
Are you talking about the CBD Cream which they PR’d years ago????
1,000 units or $1,000 worth of units??
How do you know this?
Followers
|
615
|
Posters
|
|
Posts (Today)
|
15
|
Posts (Total)
|
74026
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |